Updating the natural history of human papillomavirus and anogenital cancers

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Moscicki, Anna Barbara ^a   Schiffman, Mark ^b   Burchell, Ann ^c,d,e   Albero, Ginesa ^f,g   Giuliano, Anna R ^h   Goodman, Marc T ⁱ   Kjaer, Susanne K ^j,k   Palefsky, Joel ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ONTARIO HIV TREATMENT NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^j DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Anal disease; HPV; Male infections; Natural history; Transmission

Indexed keywords

ANUS CANCER; ANUS CARCINOMA; CANCER INCIDENCE; CANCER RISK; FEMALE; FEMALE GENITAL TRACT CANCER; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; MALE; MALE GENITAL TRACT CANCER; MEDICAL HISTORY; PAPILLOMAVIRUS INFECTION; PENILE INTRAEPITHELIAL NEOPLASIA; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REINFECTION; REVIEW; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

EID: 84876418361     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.089     Document Type: Review

References (85)

1. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24(Suppl 3):S42-51.
2. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100(7):513-7.
3. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102(5):315-24.
4. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011;20(4):699-707.
5. Kovacs K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, et al. A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31,000 women in West Germany. Eur J Cancer Prev 2009;18(4):307-15.
6. Moscicki AB, Widdice L, Ma Y, Farhat S, Miller-Benningfield S, Jonte J, et al. Comparison of natural histories of human papillomavirus detected by clinicianand self-sampling. Int J Cancer 2010;127(8):1882-92.
7. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010;70(8):3159-69.
8. Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, et al. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011;203(6):814-22.
9. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 2012;30(S5): F100-6.
10. Sundstrom K, Eloranta S, Sparen P, Arnheim Dahlstrom L, Gunnell A, Lindgren A, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19(10):2469-78.
11. Dahlstrom LA, Ylitalo N, Sundstrom K, Palmgren J, Ploner A, Eloranta S, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127(8):1923-30.
12. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191(5):731-8.
13. Moscicki AB, Ma Y, Jonte J, Miller-Benningfield S, Hanson E, Jay J, et al. The role of sexual behavior and human papillomavirus persistence in predicting repeated infections with new human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2010;19(8):2055-65.
14. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Low risk of cervical intraepithelial neoplasia grade 2/3 after reappearance of type-specific carcinogenic HPV. Int J Cancer 2012;131(8): 1874-81.
15. Syrjanen K, Shabalova I, Naud P, Derchain S, Sarian L, Kozachenko V, et al. Cofactors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3. Int J STD AIDS 2011;22(5):263-72.
16. Moscicki AB, Ma Y, Wibbelsman C, Powers A, Darragh TM, Farhat S, et al. Risks for cervical intraepithelial neoplasia 3 among adolescents and young women with abnormal cytology. Obstet Gynecol 2008;112(6):1335-42.
17. Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 2010;82(4):616-23.
18. Denny LA, Franceschi S, de Sanjosé S, Heard I, Moscicki A-B, Palefsky J. Human papillomavirus, human immune deficiency virus and immunosuppression. Vaccine 2012;30(S5):F168-74.
19. Hwang LY, Ma Y, Benningfield SM, Clayton L, Hanson EN, Jay J, et al. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health 2009;44(2):103-10.
20. Louie KS, de Sanjosé S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer 2009;100(7): 1191-7.
21. Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 2010;102(23): 1794-804.
22. Moscicki AB, Ma Y, Jonte J, Benningfield-Miller S, Jay J, Hanson L, et al. Reactivation vs. New HPV-16 Detection. In: 27th International Papillomavirus Conference and Clinical Workshop. 2011.
23. Daud II, Scott ME, Ma Y, Shiboski S, Farhat S, Moscicki AB. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 2011;128(4):879-86.
24. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009;19(4):508-12.
25. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010;70(21): 8569-77.
26. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV viruslike particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009;22(6):445-9.
27. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011;204(1):94-102.
28. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19): 1915-27.
29. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14.
30. Xi LF, Koutsky LA, Castle PE, Edelstein ZR, Hulbert A, Schiffman M, et al. Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. J Infect Dis 2010;202(11):1667-70. PMCID: PMC3107552.
31. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008;14(6):888-94.
32. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116(6):1373-80.
33. McAllum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail AK. Is the treatment of CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol 2011;205(5), 478.e1-7.
34. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009;9:119.
35. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113(1):18-25.
36. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011;128(12):2898-910.
37. Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, et al. Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies. Proteome Sci 2011;9:36.
38. Burchell AN, Coutlee F, Tellier PP, Hanley J, Franco EL. Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples. J Infect Dis 2011;204(11):1723-9.
39. Hernandez BY, Shvetsov YB, Goodman MT, Wilkens LR, Thompson P, Zhu X, et al. Reduced clearance of penile human papillomavirus infection in uncircumcised men. J Infect Dis 2010;201(9):1340-3.
40. Mbulawa ZZA, Marais DJ, Coetzee D, Williamson AL. HPV transmission in heterosexually active couples over 12 months. Oral presentation 316. In: The 26th International Papillomavirus Conference. 2010.
41. Widdice L, Ma Y, Farhat S, Jonte J, Breland D, Moscicki AB. Concordance and transmission of human papillomavirus. Poster P-612. In: 26th International Papillomavirus Conference. 2010.
42. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011;377(9769):932-40.
43. Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010;171(7):817-25.
44. Baay MF, Francois K, Lardon F, Van Royen P, Pauwels P, Vermorken JB, et al. The presence of Y chromosomal deoxyribonucleic acid in the female vaginal swab: possible implications for human papillomavirus testing. Cancer Epidemiol 2011;35(1):101-3.
45. Bleeker MC, Snijders PF, Voorhorst FJ, Meijer CJ. Flat penile lesions: the infectious "invisible" link in the transmission of human papillomavirus. Int J Cancer 2006;119(11):2505-12.
46. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPVassociated lesions. J Clin Virol 2006;35(3):270-7.
47. Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103(4):519-24.
48. Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, van Diemen PM, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005;41(5):612-20.
49. Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010;39(1):166-81.
50. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009;199(9):1263-9.
51. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Ning L, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008;197(7):957-66.
52. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001;183(3):383-91.
53. Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138(6):453-9.
54. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis 2010;201(9):1331-9.
55. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007;196(8):1128-36.
56. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, et al. Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev 2010;19(7):1682-5.
57. Widdice LE, Breland DJ, Jonte J, Farhat S, Ma Y, Leonard AC, et al. Human papillomavirus concordance in heterosexual couples. J Adolesc Health 2010;47(2):151-9.
58. Giuliano AR, Lazcano E, Villa LL, Flores R, Salmeron J, Lee JH, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 2009;124(6):1251-7.
59. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira Jr ED, Penny ME, et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011;203(1):58-65.
60. Goldstone S, Palefsky JM, Giuliano AR, Moreira Jr ED, Aranda C, Jessen H, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis 2011;203(1):66-74.
61. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Lu B, Smith D, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: The HIM study. Sex Transm Dis 2011;38(10):932-40.
62. Albero G, Castellsagué X, Giuliano AR, Bosch FX. Male circumcision and genital Human Papillomavirus: a systematic review and meta-analysis. Sex Transm Dis 2012;39(2):104-13.
63. Nielson CM, Harris RB, Nyitray AG, Dunne EF, Stone KM, Giuliano AR. Consistent condom use is associated with lower prevalence of human papillomavirus infection in men. J Infect Dis 2010;202(3):445-51.
64. Schabath MB, Villa LL, Lazcano-Ponce E, Salmeron J, Quiterio MQ, Giuiliano AR. Smoking and human papillomavirus (HPV) infection in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev 2012;21(1):102-10.
65. Smith JS, Backes DM, Hudgens MG, Bailey RC, Veronesi G, Bogaarts M, et al. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int J Cancer 2010;126(2):572-7.
66. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200(7):1059-67.
67. Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev 2011;20(5): 990-1002.
68. Gray RH, Serwadda D, Kong X, Makumbi F, Kigozi G, Gravitt PE, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010;201(10):1455-62.
69. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2011;72(3):676-85.
70. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Prev Med 2011;53(Suppl 1):S36-41.
71. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30(S5):F12-23.
72. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101(2):281-8.
73. Nyitray AG, Smith D, Villa L, Lazcano-Ponce E, Abrahamsen M, Papenfuss M, et al. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis 2010;201(10):1498-508.
74. Shvetsov YB, Hernandez BY, McDuffie K, Wilkens LR, Zhu X, Ning L, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis 2009;48(5):536-46.
75. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190(1):37-45.
76. Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med 2008;149(5):300-6.
77. Santoso JT, Long M, Crigger M, Wan JY, Haefner HK. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol 2010;116(3):578-82.
78. Jacyntho CM, Giraldo PC, Horta AA, Grandelle R, Goncalves AK, Fonseca T, Eleuterio Jr J. Association between genital intraepithelial lesions and anal squamous intraepithelial lesions in HIV-negative women. Am J Obstet Gynecol 2011;205(2):115.e111-5.
79. Patel HS, Silver AR, Levine T, Williams G, Northover JM. Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg 2010;97(11):1716-21.
80. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 2008;337(7676):969-72.
81. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360(14):1385-94. PubMed PMID: 19339719.
82. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102(19):1478-88.
83. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. A longterm prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011;20(7):1398-409.
84. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for humanpapillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011 Jul;12(7):663-72. Erratum in: Lancet Oncol 2011;12(8):722. PubMed PMID: 21684207.
85. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011;103(18):1387-96.